Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1978 Feb 1;147(2):409–421. doi: 10.1084/jem.147.2.409

Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin

PMCID: PMC2184494  PMID: 624904

Abstract

Native rat mast cell macromolecular heparin proteoglycan and commercial hog heparin glycosaminoglycan chains inhibit generation of the amplification convertase, C3b, Bb. The inhibitory action of heparin is not due to chelation of magnesium. Heparin is most active in inhibiting convertase formation on cellular intermediates formed with the lowest C3b input and developed with the highest B concentration, thereby suggesting the receptor site for B on C3b as the point of heparin action. This interpretation is consistent with the demonstration that heparin prevents B utilization during the fluid phase interaction of C3b, B, and D. Inhibition is observed also when C3b,Bb generation takes place on cellular intermediates in the presence of P or C3NeF, which yield stabilized forms of the convertase. 50 times the concentration of heparin required to inhibit convertase generation does not accelerate the decay of the unstabilized or the C3NeF-stabilized convertases and has only a modest effect on the P-stabilized convertase. An additional effect of heparin is to impair beta1H-mediated decay-dissociation of C3b,Bb. The concentration of native or commercial heparin which prevents convertase formation is in the same range as that required for the demonstration of its anti-coagulant and anti-thrombin III cofactor activities. The additional finding that this inhibitory action of heparin can be expressed by the isolated mast cell granule suggests that native heparin may contribute to the modulation of the amplification pathway of complement.

Full Text

The Full Text of this article is available as a PDF (740.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BITTER T., MUIR H. M. A modified uronic acid carbazole reaction. Anal Biochem. 1962 Oct;4:330–334. doi: 10.1016/0003-2697(62)90095-7. [DOI] [PubMed] [Google Scholar]
  2. Baker P. J., Lint T. F., McLeod B. C., Behrends C. L., Gewurz H. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J Immunol. 1975 Feb;114(2 Pt 1):554–558. [PubMed] [Google Scholar]
  3. Ballow M., Cochrane C. G. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol. 1969 Nov;103(5):944–952. [PubMed] [Google Scholar]
  4. Brai M., Osler A. G. Studies of the C3 shunt activation in cobra venom induced lysis of unsensitized erythrocytes. Proc Soc Exp Biol Med. 1972 Jul;140(3):1116–1121. doi: 10.3181/00379727-140-36623. [DOI] [PubMed] [Google Scholar]
  5. Daha M. R., Fearon D. T., Austen K. F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976 Jan;116(1):1–7. [PubMed] [Google Scholar]
  6. Fearon D. T., Austen K. F. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683–1687. doi: 10.1073/pnas.74.4.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fearon D. T., Austen K. F. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med. 1977 Jul 1;146(1):22–33. doi: 10.1084/jem.146.1.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fearon D. T., Austen K. F. Initiation of C3 cleavage in the alternative complement pathway. J Immunol. 1975 Nov;115(5):1357–1361. [PubMed] [Google Scholar]
  9. Fearon D. T., Austen K. F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975 Oct 1;142(4):856–863. doi: 10.1084/jem.142.4.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fearon D. T., Austen K. F. Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3220–3224. doi: 10.1073/pnas.72.8.3220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fearon D. T., Austen K. F., Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med. 1973 Dec 1;138(6):1305–1313. doi: 10.1084/jem.138.6.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gitlin J. D., Rosen F. S., Lachmann P. J. The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med. 1975 May 1;141(5):1221–1226. doi: 10.1084/jem.141.5.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hunsicker L. G., Ruddy S., Austen K. F. Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol. 1973 Jan;110(1):128–138. [PubMed] [Google Scholar]
  14. Kaplan A. P., Austen K. F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696–712. doi: 10.1084/jem.133.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kierszenbaum F., Weinman D. Antibody-independent activation of the alternative complement pathway in human serum by parasitic cells. Immunology. 1977 Feb;32(2):245–249. [PMC free article] [PubMed] [Google Scholar]
  16. Loos M., Volanakis J. E., Stroud R. M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry. 1976 Mar;13(3):257–261. doi: 10.1016/0019-2791(76)90224-x. [DOI] [PubMed] [Google Scholar]
  17. Loos M., Volanakis J. E., Stroud R. M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry. 1976 Sep;13(9):789–791. doi: 10.1016/0019-2791(76)90202-0. [DOI] [PubMed] [Google Scholar]
  18. MIKHAIL G. R., MILLER-MILINSKA A. MAST CELL POPULATION IN HUMAN SKIN. J Invest Dermatol. 1964 Oct;43:249–254. [PubMed] [Google Scholar]
  19. Müller-Eberhard H. J., Götze O. C3 proactivator convertase and its mode of action. J Exp Med. 1972 Apr 1;135(4):1003–1008. doi: 10.1084/jem.135.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nelson R. A., Jr, Jensen J., Gigli I., Tamura N. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry. 1966 Mar;3(2):111–135. doi: 10.1016/0019-2791(66)90292-8. [DOI] [PubMed] [Google Scholar]
  22. OSLER A. G., RANDALL H. G., HILL B. M., OVARY Z. Studies on the mechanism of hypersensitivity phenomena. III. The participation of complement in the formation of anaphylatoxin. J Exp Med. 1959 Aug 1;110(2):311–339. doi: 10.1084/jem.110.2.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Raepple E., Hill H. U., Loos M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry. 1976 Mar;13(3):251–255. doi: 10.1016/0019-2791(76)90223-8. [DOI] [PubMed] [Google Scholar]
  25. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  26. SCOTT J. E. Aliphatic ammonium salts in the assay of acidic polysaccharides from tissues. Methods Biochem Anal. 1960;8:145–197. doi: 10.1002/9780470110249.ch4. [DOI] [PubMed] [Google Scholar]
  27. Sher A. Complement-dependent adherence of mast cells to schistosomula. Nature. 1976 Sep 23;263(5575):334–336. doi: 10.1038/263334a0. [DOI] [PubMed] [Google Scholar]
  28. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]
  29. Weiler J. M., Daha M. R., Austen K. F., Fearon D. T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268–3272. doi: 10.1073/pnas.73.9.3268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Yurt R. W., Leid R. W., Jr, Austen K. F. Native heparin from rat peritoneal mast cells. J Biol Chem. 1977 Jan 25;252(2):518–521. [PubMed] [Google Scholar]
  31. Yurt R. W., Leid R. W., Jr, Spragg J., Austen K. F. Immunologic release of heparin from purified rat peritoneal mast cells. J Immunol. 1977 Apr;118(4):1201–1207. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES